Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Theravance Biopharma stock | $18.04

Own Theravance Biopharma stock in just a few minutes.

Fact checked

Theravance Biopharma, Inc is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 316 staff and has a trailing 12-month revenue of around USD$82.6 million.

How to buy shares in Theravance Biopharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Theravance Biopharma. Find the stock by name or ticker symbol: TBPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Theravance Biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.04, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Theravance Biopharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Theravance Biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Theravance Biopharma share price

Use our graph to track the performance of TBPH stocks over time.

Theravance Biopharma shares at a glance

Information last updated 2020-12-04.
Latest market closeUSD$18.04
52-week rangeUSD$14.48 - USD$31.54
50-day moving average USD$18.0691
200-day moving average USD$19.7048
Wall St. target priceUSD$31.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.05

Buy Theravance Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Theravance Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theravance Biopharma price performance over time

Historical closes compared with the close of $18.04 from 2020-12-09

1 week (2021-01-08) N/A
1 month (2020-12-15) N/A
3 months (2020-10-15) N/A
6 months (2020-07-15) N/A
1 year (2020-01-15) N/A
2 years (2019-01-15) N/A
3 years (2018-01-15) N/A
5 years (2016-01-15) N/A

Theravance Biopharma financials

Revenue TTM USD$82.6 million
Gross profit TTM USD$-145,834,000
Return on assets TTM -38.1%
Return on equity TTM 0%
Profit margin 0%
Book value $-2.423
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Theravance Biopharma shares

There are currently 3.5 million Theravance Biopharma shares held short by investors – that's known as Theravance Biopharma's "short interest". This figure is 0.4% up from 3.5 million last month.

There are a few different ways that this level of interest in shorting Theravance Biopharma shares can be evaluated.

Theravance Biopharma's "short interest ratio" (SIR)

Theravance Biopharma's "short interest ratio" (SIR) is the quantity of Theravance Biopharma shares currently shorted divided by the average quantity of Theravance Biopharma shares traded daily (recently around 374344.82029598). Theravance Biopharma's SIR currently stands at 9.46. In other words for every 100,000 Theravance Biopharma shares traded daily on the market, roughly 9460 shares are currently held short.

However Theravance Biopharma's short interest can also be evaluated against the total number of Theravance Biopharma shares, or, against the total number of tradable Theravance Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theravance Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Theravance Biopharma shares in existence, roughly 60 shares are currently held short) or 0.1405% of the tradable shares (for every 100,000 tradable Theravance Biopharma shares, roughly 141 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Theravance Biopharma.

Find out more about how you can short Theravance Biopharma stock.

Theravance Biopharma share dividends

We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.

Theravance Biopharma share price volatility

Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $14.48 up to $31.54. A popular way to gauge a stock's volatility is its "beta".

TBPH.US volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.9554. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).

Theravance Biopharma overview

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site